Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases. The company is headquartered in Calgary, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-403-2549252
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/20/2020 (Estimated)
OptionableNot Optionable
Resverlogix (TSE:RVX) Frequently Asked Questions
What is Resverlogix's stock symbol?
Resverlogix trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX."
When is Resverlogix's next earnings date?
What is the consensus analysts' recommendation for Resverlogix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Resverlogix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Resverlogix.
Has Resverlogix been receiving favorable news coverage?
Media stories about RVX stock have trended very negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Resverlogix earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Resverlogix.
Who are some of Resverlogix's key competitors?
Some companies that are related to Resverlogix include BELLUS Health (BLU), Paradigm Biopharmaceuticals (PAR), CEL-SCI (CVM), Cel-Sci (CVM), Oxford BioMedica (OXB), Bellus Health (BLU), Starpharma (SPL), Pfenex (PFNX), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Trillium Therapeutics (TRIL), Biotest (BIO), Silence Therapeutics (SLN), Rafael (RFL) and ProMetic Life Sciences (PLI).
What other stocks do shareholders of Resverlogix own?
Who are Resverlogix's key executives?
Resverlogix's management team includes the folowing people:
- Mr. Donald J. McCaffrey, Co-Founder, Pres, CEO & Chairman
- Mr. Aaron Bradley Cann CA, CPA, CBV, Chief Financial Officer
- Mr. Kenneth Eugene Lebioda BA, Sr. VP of Bus. & Corp. Devel.
- Dr. Jan O. Johansson, Sr. VP of Medical Affairs
- Dr. Michael Sweeney, Sr. VP of Clinical Devel. (Age 58)
How do I buy shares of Resverlogix?
Shares of RVX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Resverlogix's stock price today?
One share of RVX stock can currently be purchased for approximately C$1.31.
How big of a company is Resverlogix?
What is Resverlogix's official website?
How can I contact Resverlogix?
Resverlogix's mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company can be reached via phone at +1-403-2549252.
MarketBeat Community Rating for Resverlogix (TSE RVX)
MarketBeat's community ratings are surveys of what our community members think about Resverlogix and other stocks. Vote "Outperform" if you believe RVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
